R&D

R&D

Agios Scraps Sickle Cell Drug Tebapivat After Mid-Stage Disappointment

The company said its next-generation pyruvate kinase activator failed to show enough differentiation, ceding ground to a rival Novo Nordisk therapy.

1 hr ago · 2 min read

R&D

Crystalys Raises $130M to Advance Its Gout Drug Through Late-Stage Trials

The Series B will fund Phase 2 and Phase 3 studies of dotinurad, a uric-acid-lowering therapy already approved in several Asian markets.

10 hr ago · 2 min read